The FDA’s refuse-to-file letter cited no safety or efficacy concerns for Moderna’s influenza vaccine, mRNA-1010. The company said the agency’s justification for refusing a review is inconsistent with ...

OpenEvidence’s $12 billion valuation reflects investor confidence in its bottom-up, doctor-first model. It has driven rapid adoption, with more than 757,000 clinicians using the startup’s free AI ...

Telepsychiatry provider Talkiatry has raised a $210 million Series D round led by Perceptive Advisors, bringing its total funding to more than $400 million. CEO Robert Krayn said the company is ...

The Consolidated Appropriations Act of 2026 and the Department of Labor’s proposed rule implement major PBM reforms for employers, but don’t include everything they want, including a ban on spread ...

NYU Langone Health is partnering with Isaac Health to launch a specialist-led virtual care model aimed at reducing long waits for memory care. The partnership will test whether telehealth can expand ...

Health advocate network Solace Health gained unicorn status after closing a $130 million Series C funding round. The startup’s advocates help with tasks like scheduling appointments, finding ...

HHS is scrapping its proposed 340B rebate pilot after hospitals sued to stop it. Providers say the plan would have created cash flow problems and administrative burdens that threatened safety-net care ...

Digital health is entering a more mature phase in 2026 as consolidation accelerates through targeted M&A, driven by the need for scale, artificial intelligence and pressure from payers, investors say.

Virtual women’s health provider Midi Health has reached unicorn status after raising a $100 million Series D, with investors backing its insurance-covered, direct-to-consumer model. The company is ...

A BridgeBio Pharma drug developed for dwarfism increased children’s growth rates in a pivotal clinical trial, meeting the study’s main goal and boosting the daily pill’s chances to offer an ...

The next frontier for cell therapy is shaping up to be in vivo treatments for autoimmune disease, and Eli Lilly is getting a contender through the acquisition of startup Orna Therapeutics for up to $2 ...